1
|
Kostyuk AI, Rapota DD, Morozova KI, Fedotova AA, Jappy D, Semyanov AV, Belousov VV, Brazhe NA, Bilan DS. Modern optical approaches in redox biology: Genetically encoded sensors and Raman spectroscopy. Free Radic Biol Med 2024; 217:68-115. [PMID: 38508405 DOI: 10.1016/j.freeradbiomed.2024.03.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/22/2023] [Revised: 02/10/2024] [Accepted: 03/13/2024] [Indexed: 03/22/2024]
Abstract
The objective of the current review is to summarize the current state of optical methods in redox biology. It consists of two parts, the first is dedicated to genetically encoded fluorescent indicators and the second to Raman spectroscopy. In the first part, we provide a detailed classification of the currently available redox biosensors based on their target analytes. We thoroughly discuss the main architecture types of these proteins, the underlying engineering strategies for their development, the biochemical properties of existing tools and their advantages and disadvantages from a practical point of view. Particular attention is paid to fluorescence lifetime imaging microscopy as a possible readout technique, since it is less prone to certain artifacts than traditional intensiometric measurements. In the second part, the characteristic Raman peaks of the most important redox intermediates are listed, and examples of how this knowledge can be implemented in biological studies are given. This part covers such fields as estimation of the redox states and concentrations of Fe-S clusters, cytochromes, other heme-containing proteins, oxidative derivatives of thiols, lipids, and nucleotides. Finally, we touch on the issue of multiparameter imaging, in which biosensors are combined with other visualization methods for simultaneous assessment of several cellular parameters.
Collapse
Affiliation(s)
- Alexander I Kostyuk
- M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997, Russia; Pirogov Russian National Research Medical University, 117997, Moscow, Russia
| | - Diana D Rapota
- M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997, Russia
| | - Kseniia I Morozova
- Faculty of Biology, M.V. Lomonosov Moscow State University, Moscow, 119234, Russia
| | - Anna A Fedotova
- M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997, Russia; Faculty of Biology, M.V. Lomonosov Moscow State University, Moscow, 119234, Russia
| | - David Jappy
- Federal Center of Brain Research and Neurotechnologies, Federal Medical Biological Agency, Moscow, 117997, Russia
| | - Alexey V Semyanov
- M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997, Russia; Faculty of Biology, M.V. Lomonosov Moscow State University, Moscow, 119234, Russia; Sechenov First Moscow State Medical University, Moscow, 119435, Russia; College of Medicine, Jiaxing University, Jiaxing, Zhejiang Province, 314001, China
| | - Vsevolod V Belousov
- M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997, Russia; Pirogov Russian National Research Medical University, 117997, Moscow, Russia; Federal Center of Brain Research and Neurotechnologies, Federal Medical Biological Agency, Moscow, 117997, Russia; Life Improvement by Future Technologies (LIFT) Center, Skolkovo, Moscow, 143025, Russia
| | - Nadezda A Brazhe
- M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997, Russia; Faculty of Biology, M.V. Lomonosov Moscow State University, Moscow, 119234, Russia.
| | - Dmitry S Bilan
- M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997, Russia; Pirogov Russian National Research Medical University, 117997, Moscow, Russia.
| |
Collapse
|
2
|
Flynn CD, Chang D, Mahmud A, Yousefi H, Das J, Riordan KT, Sargent EH, Kelley SO. Biomolecular sensors for advanced physiological monitoring. Nat Rev Bioeng 2023; 1:1-16. [PMID: 37359771 PMCID: PMC10173248 DOI: 10.1038/s44222-023-00067-z] [Citation(s) in RCA: 15] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Accepted: 04/06/2023] [Indexed: 06/28/2023]
Abstract
Body-based biomolecular sensing systems, including wearable, implantable and consumable sensors allow comprehensive health-related monitoring. Glucose sensors have long dominated wearable bioanalysis applications owing to their robust continuous detection of glucose, which has not yet been achieved for other biomarkers. However, access to diverse biological fluids and the development of reagentless sensing approaches may enable the design of body-based sensing systems for various analytes. Importantly, enhancing the selectivity and sensitivity of biomolecular sensors is essential for biomarker detection in complex physiological conditions. In this Review, we discuss approaches for the signal amplification of biomolecular sensors, including techniques to overcome Debye and mass transport limitations, and selectivity improvement, such as the integration of artificial affinity recognition elements. We highlight reagentless sensing approaches that can enable sequential real-time measurements, for example, the implementation of thin-film transistors in wearable devices. In addition to sensor construction, careful consideration of physical, psychological and security concerns related to body-based sensor integration is required to ensure that the transition from the laboratory to the human body is as seamless as possible.
Collapse
Affiliation(s)
- Connor D. Flynn
- Department of Chemistry, Faculty of Arts & Science, University of Toronto, Toronto, ON Canada
- Department of Chemistry, Weinberg College of Arts & Sciences, Northwestern University, Evanston, IL USA
| | - Dingran Chang
- Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON Canada
| | - Alam Mahmud
- The Edward S. Rogers Sr Department of Electrical and Computer Engineering, University of Toronto, Toronto, ON Canada
| | - Hanie Yousefi
- Department of Biomedical Engineering, McCormick School of Engineering, Northwestern University, Evanston, IL USA
| | - Jagotamoy Das
- Department of Chemistry, Weinberg College of Arts & Sciences, Northwestern University, Evanston, IL USA
| | - Kimberly T. Riordan
- Department of Chemistry, Weinberg College of Arts & Sciences, Northwestern University, Evanston, IL USA
| | - Edward H. Sargent
- Department of Chemistry, Weinberg College of Arts & Sciences, Northwestern University, Evanston, IL USA
- The Edward S. Rogers Sr Department of Electrical and Computer Engineering, University of Toronto, Toronto, ON Canada
- Department of Electrical and Computer Engineering, McCormick School of Engineering, Northwestern University, Evanston, IL USA
| | - Shana O. Kelley
- Department of Chemistry, Faculty of Arts & Science, University of Toronto, Toronto, ON Canada
- Department of Chemistry, Weinberg College of Arts & Sciences, Northwestern University, Evanston, IL USA
- Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON Canada
- Department of Biomedical Engineering, McCormick School of Engineering, Northwestern University, Evanston, IL USA
- Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Evanston, IL USA
- International Institute for Nanotechnology, Northwestern University, Evanston, IL USA
- Chan Zuckerberg Biohub Chicago, Chicago, IL USA
| |
Collapse
|
3
|
Schuster J, Mahler HC, Joerg S, Huwyler J, Mathaes R. Analytical Challenges Assessing Protein Aggregation and Fragmentation Under Physiologic Conditions. J Pharm Sci 2021; 110:3103-3110. [PMID: 33933436 DOI: 10.1016/j.xphs.2021.04.014] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2020] [Revised: 03/01/2021] [Accepted: 04/09/2021] [Indexed: 12/17/2022]
Abstract
Therapeutic proteins are administered by injection or infusion. After administration, the physiologic environment in the desired body compartment - fluid or tissue - can impact protein stability and lead to changes in the safety and/or efficacy profile. For example, protein aggregation and fragmentation are critical quality attributes of the drug product and can occur after administration to patients. In this context, the in vivo stability of therapeutic proteins has gained increasing attention. However, in vivo protein aggregation and fragmentation are difficult to assess and have been rarely investigated. This mini-review summarizes analytical approaches to assess the stability of therapeutic proteins using simulated physiologic conditions. Furthermore, we discuss factors potentially causing in vivo protein aggregation, precipitation, and fragmentation in complex biological fluids. Different analytical approaches are evaluated with respect to their applicability and possible shortcomings when it comes to these degradation events in biological fluids. Tracking protein stability in biological fluids typically requires purifying or labeling the protein of interest to circumvent matrix interference of biological fluids. Improved analytical methods are strongly needed to gain knowledge on in vivo protein aggregation and fragmentation. In vitro models can support the selection of lead candidates and accelerate the pre-clinical development of therapeutic proteins.
Collapse
Affiliation(s)
- Joachim Schuster
- Lonza Pharma and Biotech, Drug Product Services, Basel, Switzerland; University of Basel, Pharmacenter, Division of Pharmaceutical Technology, Basel, Switzerland
| | | | - Susanne Joerg
- Lonza Pharma and Biotech, Drug Product Services, Basel, Switzerland
| | - Joerg Huwyler
- University of Basel, Pharmacenter, Division of Pharmaceutical Technology, Basel, Switzerland
| | - Roman Mathaes
- Lonza Pharma and Biotech, Drug Product Services, Basel, Switzerland.
| |
Collapse
|
4
|
Kim MT, Lechmann M, Rajan S, Shivva V, Lee A, Chen Y, Weis DD. In Vivo Reoxidation Kinetics of Free Thiols in Multiple Domains of IgG1 Antibodies in Rats. J Pharm Sci 2021; 110:1989-1996. [PMID: 33617870 DOI: 10.1016/j.xphs.2021.02.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2020] [Revised: 02/08/2021] [Accepted: 02/09/2021] [Indexed: 11/28/2022]
Abstract
While free thiols in monoclonal antibodies (mAbs) have been extensively characterized by in vitro studies to probe its effect on antibody function and stability, their in vivo biotransformation has not been comprehensively studied. In this study, a panel of five recombinant IgG1 mAbs with elevated free thiols in the VH, VL, and CH2 domains were intravenously administered into Wistar rats. In vivo biotransformation of thirty-five free thiol sites in total (7 disulfide pairs in VL, CL, VH, CH1, HH, CH2, CH3 domains across the 5 mAbs) were monitored using a denaturing differential isotopic tagging procedure on immunopurified timepoints followed by LC-MS of tryptic digests. The free thiol levels in two VH domain and one CH2 domain disulfide sites decreased in vivo following first order kinetics. Free thiol levels of the remaining 32 sites were remarkably stable in vivo. Further analytical characterization highlighted a positive association between a free thiol's solvent accessibility and a free thiol's reoxidation propensity. The data and discussion presented here shed valuable insights into the in vivo fate of free thiols in several recombinant IgG1s and its implications for free thiols as a product quality attribute in therapeutic mAb products.
Collapse
Affiliation(s)
- Michael T Kim
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California, USA; Department of Chemistry, University of Kansas, Lawrence, Kansas, USA.
| | - Martin Lechmann
- Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Munich, Penzberg, Germany
| | - Sharmila Rajan
- Department of Preclinical and Translation Pharmacokinetics, Genentech, South San Francisco, California, USA
| | - Vittal Shivva
- Department of Preclinical and Translation Pharmacokinetics, Genentech, South San Francisco, California, USA
| | - Aron Lee
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California, USA
| | - Yan Chen
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California, USA
| | - David D Weis
- Department of Chemistry, University of Kansas, Lawrence, Kansas, USA
| |
Collapse
|
5
|
Darriba ML, Cerutti ML, Bruno L, Cassataro J, Pasquevich KA. Stability Studies of the Vaccine Adjuvant U-Omp19. J Pharm Sci 2020; 110:707-718. [PMID: 33058898 PMCID: PMC7815325 DOI: 10.1016/j.xphs.2020.10.011] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2020] [Revised: 09/24/2020] [Accepted: 10/08/2020] [Indexed: 01/18/2023]
Abstract
Unlipidated outer membrane protein 19 (U-Omp19) is a novel mucosal adjuvant in preclinical development to be used in vaccine formulations. U-Omp19 holds two main properties, it is capable of inhibiting gastrointestinal and lysosomal peptidases, increasing the amount of co-administered antigen that reaches the immune inductive sites and its half-life inside cells, and it is able to stimulate antigen presenting cells in vivo. These activities enable U-Omp19 to enhance the adaptive immune response to co-administrated antigens. To characterize the stability of U-Omp19 we have performed an extensive analysis of its physicochemical and biological properties in a 3-year long-term stability study, and under potentially damaging freeze-thawing and lyophilization stress processes. Results revealed that U-Omp19 retains its full protease inhibitor activity, its monomeric state and its secondary structure even when stored in solution for 36 months or after multiple freeze-thawing cycles. Non-enzymatic hydrolysis resulted the major degradation pathway for storage in solution at 4 °C or room temperature which can be abrogated by lyophilization yet increasing protein tendency to form aggregates. This information will play a key role in the development of a stable formulation of U-Omp19, allowing an extended shelf-life during manufacturing, storage, and shipping of a future vaccine containing this pioneering adjuvant.
Collapse
Affiliation(s)
- M Laura Darriba
- Instituto de Investigaciones Biotecnológicas (UNSAM-CONICET), Universidad Nacional de San Martín, Buenos Aires, Argentina
| | - María L Cerutti
- Fundación Instituto Leloir, IIBBA-CONICET, Buenos Aires, Argentina.
| | - Laura Bruno
- Instituto de Investigaciones Biotecnológicas (UNSAM-CONICET), Universidad Nacional de San Martín, Buenos Aires, Argentina
| | - Juliana Cassataro
- Instituto de Investigaciones Biotecnológicas (UNSAM-CONICET), Universidad Nacional de San Martín, Buenos Aires, Argentina
| | - Karina A Pasquevich
- Instituto de Investigaciones Biotecnológicas (UNSAM-CONICET), Universidad Nacional de San Martín, Buenos Aires, Argentina.
| |
Collapse
|
6
|
Machalek NS, Li C, Barton C, Yan G, Arthur KK. Universal Qualification of Near Ultraviolet Circular Dichroism Spectroscopy: Method Performance Parameters and Limits of Detection for Structural Differences. J Pharm Sci 2020; 109:3728-33. [PMID: 33002469 DOI: 10.1016/j.xphs.2020.09.038] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2020] [Revised: 09/24/2020] [Accepted: 09/25/2020] [Indexed: 11/21/2022]
Abstract
Analytical methods must be qualified as part of the method development lifecycle for product characterization of biotherapeutics. For higher order structure characterization methods, such as near ultraviolet circular dichroism spectroscopy, qualification is performed to determine the expected variability of the method and to establish criteria for analytical product comparability, reference standard qualification, and analytical similarity evaluations. Typical method qualifications require a single product to be tested across several days with multiple replicates, essential to establish a quantitative limit for future product evaluation studies, which may be burdensome with respect to time, instrumentation, and material requirements. In this note, a methodology is proposed to expedite the qualification process for the near ultraviolet circular dichroism spectroscopy method, decreasing the number of required qualification runs, in many cases, to just one for each product. The significant reduction in the number of assays for qualification is achieved by utilizing historical data that applies universally across products of variable classification, size, and test date. Despite their differences, the products exhibit comparable method performance when compared to a product-specific reference standard, and a universal detection threshold is established for application to future product evaluations that meet pre-determined method suitability criteria following a single verification run.
Collapse
|
7
|
Naji KM, Thamer FH, Numan AA, Dauqan EM, Alshaibi YM, D'souza MR. Ferric-bipyridine assay: A novel spectrophotometric method for measurement of antioxidant capacity. Heliyon 2020; 6:e03162. [PMID: 32042955 PMCID: PMC7002788 DOI: 10.1016/j.heliyon.2020.e03162] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2019] [Revised: 11/26/2019] [Accepted: 12/31/2019] [Indexed: 12/27/2022] Open
Abstract
Measurement of the antioxidant potential using in vitro assays is paramount in the assessment of various food products and nutraceuticals. Researchers always attempt to develop more accurate assays which can be performed in unsophisticated conditions. This novel method, Ferric-Bipyridine reducing capacity of total antioxidants (FBRC) is a very simple, accurate assay performed based on the reduction of Fe (III) to Fe (II) by antioxidants with the formation of a colored complex with bipyridine (Bp) i.e, Fe(II)-Bp. The FBRC method thus developed was assessed under carefully adjusted parameters of oxidant concentration, pH, temperature, solvent, light and time in order to fix the optimum conditions for the assay. The spectrophotometric monitoring of Fe(II)-Bp complex was noted by the formation of an intense pink color at room temperature with absorption maxima at 535 nm, pH 4. The analytical performance of this method was fully validated, and the obtained results were satisfactory. It was successfully applied to measure the total antioxidant capacity of standard compounds such as gallic acid, ascorbic acid and butylated hydroxy toluene (BHT), in addition to some plant extracts and oils. The FBRC method is inexpensive, reproducible and simple to perform. In addition, the antioxidant activity of the tested compounds compared to common reference methods showed that the novel FBRC method is superior to the Ferric reducing antioxidant power (FRAP) with regard to its use of realistic pH and faster kinetics. Thus, the FBRC method is convenient for the estimation of total antioxidant in plants extracts, natural products, essential oils and food stuff.
Collapse
Affiliation(s)
- Khalid Mohammed Naji
- Department of Chemistry, Faculty of Science, Sana'a University, Sana'a, Yemen.,Department of Chemical Ecology/Biological Chemistry, Konstanz University, Konstanz, Germany
| | - Faten Hameed Thamer
- Department of Chemistry, Faculty of Science, Sana'a University, Sana'a, Yemen
| | - Abdulqawi Ahmed Numan
- Department of Curricula and Methodologist Faculty of Education, Sana'a University, Sana'a, Yemen
| | - Eqbal Mohammed Dauqan
- Department of Public Health, Sport and Nutrition, Faculty of Health and Sport Science, University of Agder, Krestiansand, Norway
| | | | | |
Collapse
|
8
|
Rider T, LeBoeuf RC, Tso P, Jandacek RJ. The Use of Kits in the Analysis of Tissue Lipids Requires Validation. Lipids 2016; 51:497-504. [PMID: 26949102 DOI: 10.1007/s11745-016-4134-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2015] [Accepted: 02/16/2016] [Indexed: 10/22/2022]
Abstract
The ready availability and ease of use of kits for the measurement of serum lipids has greatly facilitated these measurements. In many cases it would be convenient to use these kits in the determination of lipid concentrations in tissues. The successful application of serum kits in tissue analysis requires that two important issues be considered. First, the solvent system for the extraction of the lipids and the solvent used for analysis by the kit must be compatible with the reactions in the kit. Second, the concentration range in the analyzed solution must be within the range for which the kit is used. We report here that lipids in liver and adipose tissues may be significantly underestimated by the use of some kits. We recommend that the use of kits for tissue analysis of lipids be validated for the specific analysis.
Collapse
|